reports
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Sup...
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer Represents Continuation of Long-Running Partnership Focused on Supporting Advancement of Novel Ophthalmic Therapeutic Toward Commercialization CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreem...
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Mill...
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head isolator filler. The buyer elected to complete the full paymen...
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin ...
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hy...
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listi...
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into em...
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore’s Sales Organization Focused on Executing Three-Pronged Growth Strategy CHASKA, Minn., May 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Mark DaFonsec...
Galectin Therapeutics Reports Financial Results for the Quarter Ended ...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week a...
Adverum Biotechnologies Reports First Quarter 2025 Financial Results a...
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneeri...
Galectin Therapeutics Presented NAVIGATE Trial Results at the European...
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis....
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TITN TITAN MACHINERY
RCKY ROCKY BRANDS
LNDC LANDEC CORP.
EXAS EXACT SCIENCES CORPORATION
CRK COMSTOCK RESOURCES INC.
BEN FRANKLIN RESOURCES INC.
ATI ALLEGHENY TECHNOLOGIES INCORPORATED
BJRI BJ'S RESTAURANTS INC.
AVH AVITA MEDICAL CDI
ATEC ALPHATEC HOLDINGS INC.
WHG WESTWOOD HOLDINGS GROUP INC.
FLGT FULGENT GENETICS
IRTC IRHYTHM TECHNOLOGIES INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
OCBI ORANGE COUNTY BANCORP
ATOM ATOMERA
FULC FULCRUM THERAPEUTICS
IESC IES HOLDINGS INC.
ADPT ADAPTIVE BIOTECHNOLOGIES
PRDO PERDOCEO EDUCATION CORP
HIMS HIMS AND HERS HEALTH INC (A)
ACHR ARCHER AVIATION INC
ASTS AST SPACEMOBILE INC
RGTI RIGETTI COMPUTING INC
SKWD SKYWARD SPECIALTY INS GROUP INC
ASPI ASP ISOTOPES INC
BTSG BRIGHTSPRING HEALTH SERVICES INC.
DAVE DAVE INC
ASMB ASSEMBLY BIOSCIENCES INC
AEVA AEVA TECHNOLOGIES INC.
BKTI BK TECHNOLOGIES CORP
ALMU AELUMA INC
ACOG ALPHA COGNITION INC
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listi...
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conferen...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands. During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development ...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and a performance stock unit (“PSU”) award for up to 370,000 shares of its common stock to Thomas D. Salus, Lifecore’s newly hi...
Galectin Therapeutics to Present at the European Association for the S...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL 2025 meeting and deliver a scientific presentation in the late-breaking oral presentation session. The meeting will be held May 7-10, 2025, in Amsterdam, Netherlands. “We are excited that data from our NAVIGATE study, evaluating belapectin, a galectin-3...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Fina...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. “We believe Ixo-vec is poised to ...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Admini...
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Th...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Na...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Result...
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 -- -- Signed Multiple Development Agreements with New and Existing Customers -- -- Strengthened Balance Sheet through Sale of Excess Capital Equipment, Raising Approximately $17.0 Million -- Conference Call Today at 4:30pm ET CHASKA, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announ...
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets...
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the I...
Galectin Therapeutics Reports 2024 Financial Results and Provides Busi...
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “In the U.S. approximately 5 million adults are affected by MASH cirrhosis and clinically significant portal hypertension. The need for new treatments that can...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LOPE GRAND CANYON EDUCATION INC.
LNDC LANDEC CORP.
HOO HERBALIFE NUTRITION LTD.
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CAAS CHINA AUTOMOTIVE SYSTEMS ADS (N SHARES)
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
AZO AUTOZONE INC.
ADMA ADMA BIOLOGICS INC
ACU ACME UNITED CORP.
OSTK OVERSTOCK.COM INC.
UVV UNIVERSAL CORP
FDP FRESH DEL MONTE PRODUCE INC.
TATT TAT TECHNOLOGIES LTD.
WMK WEIS MARKETS INC.
KINS KINGSTONE COS. INC.
NC NACCO INDUSTRIES INC. CL A
CHCI COMSTOCK HOLDING COMPANIES
VLGEA VILLAGE SUPER MARKET INC. CL A
LAUR LAUREATE EDUCATION INC. CLASS A
CMCL CALEDONIA MINING CORPORATION
ABT ABBOTT LABORATORIES
BRP BRP GROUP
GRPN GROUPON INC.
CNXC CONCENTRIX
DRVN DRIVEN BRANDS HOLDINGS
ALHC ALIGNMENT HEALTHCARE INC
ADSE ADS TEC ENERGY PLC
KLG_w WK KELLOGG CO
TRVG TRIVAGO N.V.
BG BUNGE LIMITED
IDR IDAHO STRATEGIC RESOURCES INC
DBD DIEBOLD NIXDORF INCORPORATED
CCB CHASE CAPITAL VIII CAP SEC H 8.25%
MNPR MONOPAR THERAPEUTICS INC.
AEVA AEVA TECHNOLOGIES INC.
ORLY OREILLY AUTOMOTIVE INC CDA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.